The JAK/STAT pathway is frequently dysregulated in PTCL and CTCL, resulting in uncontrolled signaling, cell proliferation, and disease progression. Recently, the JAK/STAT pathway has emerged as a promising therapeutic target, with inhibitors such as ruxolitinib and golidocitinib demonstrating clinic...
New insights into biological targeting of T-Cell malignancies (new prospects)